Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4

A Ghose, L McCann, S Makker… - … in medical oncology, 2024 - journals.sagepub.com
Ovarian cancer (OC) is the most lethal gynaecologic malignancy, attributed to its insidious
growth, non-specific symptoms and late presentation. Unfortunately, current screening …

Elevation of circulating TNF receptor 2 in cancer: A systematic meta-analysis for its potential as a diagnostic cancer biomarker

AER Kartikasari, E Cassar, MAM Razqan… - Frontiers in …, 2022 - frontiersin.org
High Tumor Necrosis Factor Receptor 2 (TNFR2) expression is characteristic of diverse
malignant cells during tumorigenesis. The protein is also expressed by many …

Volatile organic compounds as potential biomarkers for noninvasive disease detection by nanosensors: A comprehensive review

P Velusamy, CH Su, P Ramasamy, V Arun… - Critical Reviews in …, 2023 - Taylor & Francis
Biomarkers are biological molecules associated with physiological changes of the body and
aids in the detecting the onset of disease in patients. There is an urgent need for self …

Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment

M Monavarian, AT Elhaw, PW Tang, Z Javed… - Seminars in cancer …, 2022 - Elsevier
The ascites ecosystem in ovarian cancer is inhabited by complex cell types and is bathed in
an environment rich in cytokines, chemokines, and growth factors that directly and indirectly …

Recent insight about HE4 role in ovarian cancer oncogenesis

E Anastasi, A Farina, T Granato, F Colaiacovo… - International Journal of …, 2023 - mdpi.com
Currently, ovarian cancer (OC) is a target of intense biomarkers research because of its
frequent late diagnosis and poor prognosis. Serum determination of Human epididymis …

Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: Critical role of inflammation

P Gál, J Brábek, M Holub, M Jakubek, A Šedo… - Histochemistry and Cell …, 2022 - Springer
Recent evidence indicates that targeting IL-6 provides broad therapeutic approaches to
several diseases. In patients with cancer, autoimmune diseases, severe respiratory …

Diagnostic accuracy of interleukin-6 in multiple diseases: An umbrella review of meta-analyses

Z Han, J Li, X Yi, T Zhang, D Liao, J You, J Ai - Heliyon, 2024 - cell.com
Objective This review aims to conduct a comprehensive study of the diagnostic accuracy of
interleukin-6 (IL-6) for multiple diseases by utilizing existing systematic reviews and meta …

Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies

MY Han, EH Borazanci - Frontiers in Oncology, 2023 - frontiersin.org
Malignant ascites is the accumulation of fluid in the peritoneum as a result of advanced
cancer and often signifies the terminal phase of the disease. Management of malignant …

A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological–Oncological Diseases

B Szymanska, Z Lukaszewski… - Biosensors, 2023 - mdpi.com
Diagnostics based on the determination of biomarkers in body fluids will be more successful
when several biomarkers are determined. A multiple-array SPRi biosensor for the …

The Role of Interleukin 6 (IL6), Cancer Antigen—125 (CA-125), and Human Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian …

S Muhammad, RJ Azwan, RS Rita, R Susanti… - Plos one, 2023 - journals.plos.org
Introduction A study of tumor resectability in pre-operative patients with advanced epithelial
ovarian cancer is required to predict primary surgical benefits accurately. This study aims to …